Experience with tranexamic acid, an indirect fibrinolytic inhibitor, started as soon as it was
released from Shosuke Okamoto's lab in the early 1960s. It was first prescribed to females …

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

These recommendations were systematically developed on behalf of the Network for Early
Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life-
threatening monogenic disorder in humans, characterized by progressive development and …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary
kidney disease, with approximately half of the patients experiencing end-stage renal …

La poliquistosis renal autosómica dominante (PQRAD) es la causa más frecuente de
nefropatía genética y representa entre el 6 y el 10% de los pacientes en terapia de …

Objective Local forms of the tranexamic acid have been effective in treating many
haemorrhagic cases. So that the aim of the current study is to assess the effectiveness of …

Objectives To conduct a systematic review of tranexamic acid (TXA) and the risk of renal
failure from urinary clots in adult patients with hematuria. Methods A systematic review of …

Aim Tranexamic acid (TXA) is a synthetic anti‐fibrinolytic agent commonly used for the
prevention and treatment of bleeding disorders. The aim of this study is to describe the …

Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent cause of
genetic renal disease and accounts for 6–10% of patients on kidney replacement therapy …